Novel replication process (SJ-94-0007)
- *Abstract
-
A method for growing influenza virus to a high titer in mammalian cell culture by maintaining a constant trypsin concentration is provided. The resulting virus is suitable for use in vaccines after inactivation or attenuation. This method could be used to manufacture clinical grade influenza vaccine that may be used either prophylactically to prevent infection or therapeutically to treat infected patients.
Key words: influenza virus, vaccine production, mammalian cell culture, trypsin
Granted patents or published applications: U.S. Patent Nos. 5,824,536; 6,344,354
Related scientific references: Govorkova, E et al., "Replication of Influenza A viruses in a green monkey kidney continuous cell line (Vero)" J. Infect. Dis. 172:250-253 (July 1995);
Katz, JM and Webster, RG, "Antigenic and Structural characterization of multiple sub-populations of H3N2 influenza virus from an individual" Virol. 165(2):446-456 (1988);
Katz, JM and Webster RG, "Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs" J. Infect.Dis. 160(2):191-198 (1989);
Kaverin, NV and Webster, RG "Impairment of multicycle influenza growth in Vero (WHO) cells by loss of trypsin activity" J. Virol. 69(4):2700-2703 (April 1995).
- 國家/地區
- 美國
